Cargando…

Candida glabrata Biofilms: How Far Have We Come?

Infections caused by Candida species have been increasing in the last decades and can result in local or systemic infections, with high morbidity and mortality. After Candida albicans, Candida glabrata is one of the most prevalent pathogenic fungi in humans. In addition to the high antifungal drugs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rodrigues, Célia F., Rodrigues, Maria Elisa, Silva, Sónia, Henriques, Mariana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715960/ https://www.ncbi.nlm.nih.gov/pubmed/29371530 http://dx.doi.org/10.3390/jof3010011

Ejemplares similares

Combination of Posaconazole and Amphotericin B in the Treatment of Candida glabrata Biofilms
por: Rodrigues, Célia F., et al.
Publicado: (2018)

Portrait of Matrix Gene Expression in Candida glabrata Biofilms with Stress Induced by Different Drugs
por: Rodrigues, Célia F., et al.
Publicado: (2018)

The MNN2 Gene Knockout Modulates the Antifungal Resistance of Biofilms of Candida glabrata
por: Rodrigues, Célia F., et al.
Publicado: (2018)

Inflammatory Cell Recruitment in Candida glabrata Biofilm Cell-Infected Mice Receiving Antifungal Chemotherapy
por: Rodrigues, Célia F., et al.
Publicado: (2019)

Candida Species Biofilms’ Antifungal Resistance
por: Silva, Sónia, et al.
Publicado: (2017)

Transcriptional responses of Candida glabrata biofilm cells to fluconazole are modulated by the carbon source
por: Alves, Rosana, et al.
Publicado: (2020)

Biomaterials for Testicular Bioengineering: How far have we come and where do we have to go?
por: Horvath-Pereira, Bianca de Oliveira, et al.
Publicado: (2023)

Milestones in Heart Failure: How Far We Have Come and How Far We Have Left to Go
por: Gajjela, Harini, et al.
Publicado: (2021)

Immunotherapy in myeloma: how far have we come?
por: Franssen, Laurens E., et al.
Publicado: (2019)

Calcium imaging analysis – how far have we come?
por: Robbins, Miranda, et al.
Publicado: (2021)

Intravenous iron therapy: how far have we come?
por: Cançado, Rodolfo Delfini, et al.
Publicado: (2011)

Best Pharmaceuticals for Children: How Far Have We Come?
por: Mazer-Amirshahi, Maryann, et al.
Publicado: (2014)

Understanding Bioluminescence in Dinoflagellates—How Far Have We Come?
por: Valiadi, Martha, et al.
Publicado: (2013)

Gene Delivery to the Skin – How Far Have We Come?
por: Ain, Qurrat Ul, et al.
Publicado: (2021)

Overcoming Shellfish Allergy: How Far Have We Come? †
por: Wai, Christine Y.Y., et al.
Publicado: (2020)

Paediatric Surgery on the African Continent: How Far Have We Come; How Far Can We Go?
por: Numanoglu, Alp
Publicado: (2023)

Cell therapies for Parkinson's disease: how far have we come?
por: Stoker, Thomas B, et al.
Publicado: (2016)

Metals and Alzheimer’s Disease: How Far Have We Come in the Clinic?
por: Adlard, Paul A., et al.
Publicado: (2018)

Understanding blast-induced neurotrauma: how far have we come?
por: Cernak, Ibolja
Publicado: (2017)

Delineating the Risk of Lupus Nephritis: How Far Have We Come?
por: Lee, Jisoo
Publicado: (2021)

Research for Prevention of Oral/Dental Diseases: How Far Have We Come?
por: Schwendicke, F., et al.
Publicado: (2019)

Pathogenesis and Virulence of Candida albicans and Candida glabrata
por: Henriques, Mariana, et al.
Publicado: (2020)

Providing Effective Environmental Enrichment to Pigs: How Far Have We Come?
por: van de Weerd, Heleen, et al.
Publicado: (2019)

Stem-cell transplantation in multiple myeloma: how far have we come?
por: Soekojo, Cinnie Y., et al.
Publicado: (2019)

Place Identity: How Far Have We Come in Exploring Its Meanings?
por: Peng, Jianchao, et al.
Publicado: (2020)

Thermal Ablation for Papillary Thyroid Microcarcinoma: How Far We Have Come?
por: Min, Yu, et al.
Publicado: (2020)

Editorial: Functional neuroimaging in psychiatric practice: How far have we come?
por: Kundu, Prantik
Publicado: (2023)

Immunoglobulin M in Health and Diseases: How Far Have We Come and What Next?
por: Jones, Katelyn, et al.
Publicado: (2020)

Liposomal and Deoxycholate Amphotericin B Formulations: Effectiveness against Biofilm Infections of Candida spp.
por: Rodrigues, Célia F., et al.
Publicado: (2017)

Candida spp./Bacteria Mixed Biofilms
por: Rodrigues, Maria Elisa, et al.
Publicado: (2019)

Diversity of Tanaidacea (Crustacea: Peracarida) in the World's Oceans – How Far Have We Come?
por: Blazewicz-Paszkowycz, Magdalena, et al.
Publicado: (2012)

Review of Two Decades of Cholera Diagnostics – How Far Have We Really Come?
por: Dick, Michal H., et al.
Publicado: (2012)

Oncolytic virotherapy using herpes simplex virus: how far have we come?
por: Sokolowski, Nicolas AS, et al.
Publicado: (2015)

Training in robotic surgery, replicating the airline industry. How far have we come?
por: Collins, Justin William, et al.
Publicado: (2019)

Microfluidic Platforms to Unravel Mysteries of Alzheimer’s Disease: How Far Have We Come?
por: Prasanna, Pragya, et al.
Publicado: (2021)

The Role of E-Content Development in Medical Teaching: How Far Have We Come?
por: Bankar, Maithili N, et al.
Publicado: (2023)

In Search of a Data-in-Once, Electronic Health Record-Linked, Multicenter Registry—How Far We Have Come and How Far We Still Have to Go
por: Marsolo, Keith
Publicado: (2013)

Candida sp. Infections in Patients with Diabetes Mellitus
por: Rodrigues, Célia F., et al.
Publicado: (2019)

A view on dendritic cell immunotherapy in ovarian cancer: how far have we come?
por: Coosemans, A., et al.
Publicado: (2015)

How Far Have We Come in the Field of Nerve Regeneration After Trigeminal Nerve Injury?
por: Rosén, Annika, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_m9pq3mtkovh65990k7metib0qc